Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Available 1Approved for marketing 1

Sponsor Class

OTHER 3

Study Type

Expanded_access 2Interventional 1

Sponsor

Cancer Type

CNS 6Endocrine 3

Conditions

Pheochromocytoma 14Neuroendocrine Tumors 9Paraganglioma 8Neuroblastoma 7Recurrence 3Neoplasms 3Neoplasm Metastasis 2Gastro-enteropancreatic neuroendocrine tumor 1Disease 1

Interventions

3-Iodobenzylguanidine 3olaparib 1lutetium Lu 177 dotatate 1entrectinib 1entinostat 1Pemetrexed 1Paclitaxel 1Dexamethasone 1Calcium Dobesilate 1Cabergoline 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × 3-Iodobenzylguanidine × Endocrine × Clear all
NCT03015844 2024-07-05

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Northwell Health

Available
CNSEndocrine

Neuroblastoma, Pheochromocytoma, Recurrence

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

University of California, San Francisco

Phase 2 Completed
50 enrolled 7 charts
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡